Pharmacologic agents such as glucagon-like peptide 1 (GLP-1) receptor agonists represent an emerging therapeutic class that may improve metabolic control, slow the progression of liver disease, and decrease risk for decompensation in MASLD patients, although the effects in cirrhotic patients and transplant recipients have not been fully investigated [14,15,16]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.